FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
GIANT Health is delighted to welcome CareLoop to GIANT Health 2026 as part of the NHS Innovation Accelerator (NIA) Pavilion, where the team will demonstrate how remote monitoring is helping people living with severe mental illness remain well in their…
GIANT Health is delighted to welcome RealBirth to GIANT Health 2026, where the team will showcase how digital innovation is helping transform antenatal education and support more equitable maternity care across the NHS.
Access to high-quality antenatal education plays a…
Attendees
Sponsors and Exhibitors
Contact us